Therefore, it is important to explore the subgroups of BC patients that would benefit from a novel therapeutic strategy targeting the CDK1-TFCP2L1-ID2 oncogenic pathway and to identify the specific molecular biomarkers and molecular signatures for early diagnosis and prediction of the response to this targeted therapy. The gene discussed is TFCP2L1; the disease is breast cancer.